Estimate | Study year | Sample frame and sample | Study design | Diagnostic test and diagnostic criteria | Reference |
---|---|---|---|---|---|
Diabetic retinopathy | 2008 | Sample frame: Three | Clinical screening | Diagnostic test: Blood samples | [13] |
34.5% (N = 977, n = 300) | regions: Central, East, West | Diagnostic Criteria: ADA | |||
DM1: 36.2% (n = 46) | Sample: 977 diabetes patients with DM1 (n = 136) and DM2 (n = 841) | ||||
DM2: 34.2% (n = 254) | |||||
Diabetic neuropathy | |||||
44.7% (N = 977, n = 433) | |||||
DM1: 35.8% (n = 48) | |||||
DM2: 46.2% (n = 385) | |||||
End-stage renal disease | |||||
.5% (N = 977, n = 5) | |||||
DM1: 0% (n = 0) | |||||
DM2: .6% (n = 5) | |||||
Diabetic retinopathy | Dec 2008-Jun 2009 | Sample frame: Algiers province | Cross-sectional | Diagnostic test: N/A | [21] |
DMT1/2: 48.6% ± 2.9% | |||||
Diagnostic Criteria: Alfediam criteria (Association de langue française pour l'étude du diabète et des maladies métaboliques) | |||||
Males: 49.6% | |||||
Females: 50.4% | Sample: | ||||
1,152 diabetes patients; 15 years of age or older with DM1, DM2 insulin-treated (IT) and DM2 non-insulin-treated (NIT) diabetes. Divided into three groups (n = 384) based on disease duration (less than 5 years, between 5–10 years, longer than 10 years). | |||||
DM1: 47.9% ± 7.0% | |||||
DM2 (IT and NIT.): 48.7% ± 5.2% | |||||
DMT2 (IT): 70.6% ±4.6% | |||||
DMT2 (NIT): 35.2% ± 3.8% | |||||
Proliferative diabetic retinopathy: 10.9% ± 1.8% |